04:13 AM EDT, 03/27/2026 (MT Newswires) -- Astrazeneca ( AZN ) said Friday that its drug tozorakimab met its primary endpoint in two phase 3 trials in patients with chronic obstructive pulmonary disease.

The company said the trials showed that tozorakimab reduced the annualized rate of moderate-to-severe chronic obstructive pulmonary disease exacerbations compared with placebo among both former smokers and in an overall population that included smokers and patients with all stages of lung function.

The drug was also "generally well tolerated" with a "favorable" safety profile, the company said.

In addition to other ongoing phase 3 trials of tozorakimab chronic obstructive pulmonary disease, the drug is being studied in a phase 3 trial for severe viral lower respiratory tract disease and in a phase 2 trial for asthma, the company said.